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Abstract
The coordinated cross-talk from heterotrimeric G proteins to Rho GTPases is essential during a
variety of physiological processes. Emerging data suggest that members of the Gα12/13 and Gαq/11
families of heterotrimeric G proteins signal downstream to RhoA via distinct pathways. Although
studies have elucidated mechanisms governing Gα12/13-mediated RhoA activation, proteins that
functionally couple Gαq/11 to RhoA activation have remained elusive. Recently, the Dbl-family
guanine nucleotide exchange factor (GEF) p63RhoGEF/GEFT has been described as a novel
mediator of Gαq/11 signaling to RhoA based on its ability to synergize with Gαq/11 resulting in
enhanced RhoA signaling in cells. We have used biochemical/biophysical approaches with purified
protein components to better understand the mechanism by which activated Gαq directly engages
and stimulates p63RhoGEF. Basally, p63RhoGEF is autoinhibited by the Dbl homology (DH)-
associated pleckstrin homology (PH) domain; activated Gαq relieves this autoinhibition by
interacting with a highly conserved C-terminal extension of the PH domain. This unique extension
is conserved in the related Dbl-family members Trio and Kalirin and we show that the C-terminal
Rho-specific DH-PH cassette of Trio is similarly activated by Gαq.
Rho GTPases are integral regulators of gene transcription and actin cytoskeletal remodeling
during many dynamic cellular processes (1,2). Signal transduction cascades mediated by Rho
GTPases originate via the extracellular stimulation of transmembrane receptors such as G
protein-coupled receptors (GPCRs), 4 receptor tyrosine kinases, cytokine receptors, and
integrins. Of the 22 human Rho family members, RhoA, Rac1, and Cdc42 are the most
characterized, stemming from their ability to induce striking changes in cellular morphology
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upon activation (3). Numerous studies have established that RhoA activation downstream of
GPCRs is vital for a multitude of diverse physiological responses including cell migration
(4), lipid metabolism (5), vascular smooth muscle cell contraction (6–8), and cell survival/
apoptosis (9–12). GPCR-mediated activation of RhoA effectively couples signaling pathways
mediated by two distinct groups of guanine nucleotide-binding proteins: the heterotrimeric
Gα-subunits and the monomeric small GTPases. These two groups of G proteins share a
universal mechanism for guanine nucleotide binding, GTP hydrolysis, and conformational
switching between two discrete states: a GDP-bound inactive state and a GTP-bound active
state (13). Guanine nucleotide exchange factors (GEFs) activate G proteins by promoting the
release of bound GDP, allowing the subsequent binding of GTP. Active, GTP-bound G proteins
can then interact with numerous downstream effector molecules, further propagating the signal
initiated at the plasma membrane.
GPCRs function as GEFs for heterotrimeric Gα-subunits, whereas Dbl-family GEFs are the
major class of exchange factors for Rho GTPases. Dbl-family GEFs are defined by the presence
of a Dbl homology domain (DH domain), which is almost invariantly followed by a pleckstrin
homology domain (PH domain) (14). The catalytic guanine nucleotide exchange activity
resides entirely within the DH domain, although recent evidence indicates that the PH domain
can function to fine-tune this exchange activity (15,16). Previous studies have focused on the
DH-associated PH domain as a simple membrane targeting device, by virtue of its ability to
bind phosphoinositides. However, emerging evidence suggests that PH domains may also play
important regulatory roles by serving as protein-protein interaction modules (17).
The coordinated cross-talk from GPCR stimulation to RhoA activation is mediated by Dbl-
family GEFs that are responsive to activated Gα-subunits. A growing body of literature
implicates both Gα12/13 and Gαq/11 family members as upstream activators of RhoA (18–20).
Moreover, members of theGα12/13 and Gαq/11 families utilize distinct pathways to signal
downstream to RhoA (21). RhoA activation downstream of the Gα12/13 family is mediated by
the p115 family members, which consists of p115-RhoGEF, PDZ-RhoGEF, and leukemia-
associated RhoGEF. The p115 family members are directly activated by Gα12/13 via a protein-
protein interaction mediated by a highly divergent regulator of G protein signaling (RGS)
domain, but are not activated by Gαq/11 family members (22–25). Gαq/11-coupled GPCRs can
signal downstream to RhoA via a pathway distinct from Gα12/13 and independent of the
classically described Gαq/11 effector phospholipase C-β (21,26–29). However, whereas
numerous studies have elucidated mechanisms underlying Gα12/13-mediated RhoA activation,
the signaling pathways that couple Gαq/11 to RhoA activation have remained elusive.
Recently, the Dbl-family member p63RhoGEF/GEFT has been described as a novel mediator
of Gαq/11 signaling to RhoA based on its ability to synergize with Gαq/11 resulting in enhanced
RhoA signaling (30). Using cell model systems, the authors clearly demonstrate thatGαq/11-
coupled GPCR activation or overexpression of activated mutants of Gαq/11 enhance the ability
for overexpressed p63RhoGEF to activate serum response factor-dependent gene reporters.
Furthermore, using co-immunoprecipitation studies, the authors deduced that activated
Gαq/11 associates with the C-terminal half of p63RhoGEF, which contains the PH domain.
However, the mechanistic aspects underlying Gαq/11-mediated p63RhoGEF activation remain
unclear. In particular, the previous co-immunoprecipitation studies do not rule out the indirect
association ofGαq/11 with p63RhoGEF through ancillary proteins. Furthermore, it is necessary
to determine whether Gαq/11 can directly modulate the guanine nucleotide exchange activity
of p63RhoGEF using a defined in vitro system. Here we use biochemical/ biophysical
4The abbreviations used are: GPCR, G protein-coupled receptor; GEF, guanine nucleotide exchange factor; DH, Dbl homology; PH,
pleckstrin homology; RGS, regulator of G protein signaling; TEV, tobacco etch virus; MBP, maltose-binding protein; GST, glutathione
S-transferase; SPR, surface plasmon resonance.
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approaches with highly purified protein components to show that p63RhoGEF directly and
specifically associates with activated Gαq to enhance robustly the catalyzed guanine nucleotide
exchange of RhoA, RhoB, and RhoC. Therefore, p63RhoGEF is a bona fide effector of Gαq.
Furthermore, these studies strongly implicate p63RhoGEF, together with the related Dbl-




Truncation mutant constructs of human p63RhoGEF were PCR amplified from full-length
human p63RhoGEF (GenBank accession number BC012860, kindly provided by T. Wieland)
resulting in the following constructs: DH-Ct (residues 155–580), DH-Ext (residues 155– 493),
DH-PH (residues 155–472), and DH (residues 155–347). PCR products were then subcloned
into a modified pET-21a vector (Novagen) using a previously published ligation-independent
cloning strategy (31). The bacterial expression vector, pLiC-His-TEV, which encodes an N-
terminal His6 tag followed by a tobacco etch virus (TEV) cleavage site, was used to generate
vectors for the DH-Ct, DH-Ext, and DH-PH His6-tagged p63RhoGEF constructs. The
p63RhoGEF DH construct was cloned into a His6-tagged, TEV-cleavable, maltose-binding
protein (MBP) fusion vector (pLiC-His-MBP-TEV) for improved expression and solubility.
N-terminal glutathione S-transferase (GST)-tagged constructs for p63RhoGEF DH-Ext and
DH-PH were cloned into a GST fusion vector using a similar strategy. Point mutant constructs
of p63RhoGEF (F471A, L472A, N473A, L474A, Q476A, S477A, P478A, I479A, E480A,
Y481A, Q482A, R483A) were generated in the context of the His6-tagged DH-Ext using the
Quik Change site-directed mutagenesis kit (Stratagene) followed by automated sequencing to
confirm each mutation. The coding region for the C-terminal DH-Ext region of Trio (Trio-C
DH-Ext, residues 1291–2299) was PCR amplified from full-length human Trio (Gen Bank
accession number NM_007118, kindly provided by M. Strueli) and introduced into the pLiC-
His-TEV bacterial expression vector as above. Baculovirus for the new Gαi/q chimera was
constructed with the N-terminal His6 tag followed by the N-terminal sequence ofGαi1 (1–28),
TEV cleavage site, and Gαq sequence starting at Ala8. Baculovirus for the Gα13 chimera was
described in Ref. 32.
Protein Expression and Purification
All p63RhoGEF and Trio-C recombinant protein expression constructs were expressed in the
BL21 (DE3) Escherichia coli strain. Cells were grown up at 37 °C in LB media containing 0.1
mg/ml ampicillin until an A600 of ~0.6, then induced with 0.1 mM isopropyl β-D-
thiogalactopyranoside and grown up at 18 °C for ~18 h. Cells containing His6-tagged proteins
were harvested and soluble recombinant proteins were purified using standard Ni2+-affinity
chromatography followed by size-exclusion chromatography. Prior to size-exclusion
chromatography, some His6-tagged proteins were treated with TEV to remove the His6 tag.
Additionally, treatment with TEV allowed for removal of the N-terminal MBP fusion of the
p63RhoGEFDHconstruct. E. coli cells containing GST fusion p63RhoGEF proteins (GST-DH-
Ext, GST-DH-PH) were also harvested and recombinant proteins purified using standard
glutathione-affinity chromatography followed by size-exclusion chromatography. Chimeric
fusion constructs of the heterotrimeric G proteins Gαq andGα13 were purified using a
baculovirus-based expression system (Invitrogen) in High-5 insect cells based on methods
previously described (32,33). Purified protein samples for the heterotrimeric G proteins Gαi,
Gαo, Gαt, and Gαs were generously provided by C. Johnston and D. Siderovski (34,35).
Heterotrimeric Gα-subunits were confirmed active using several independent methods
including AlF4-dependent binding to effectors proteins. Additionally, Dbs DH-PH (residues
623–967), Tiam1 DH-PH (residues 1022–1406), Rac1 (residues 1–189 C189S), Cdc42
Rojas et al. Page 3













(residues 1–189 C189S), RhoA (residues 1–190 C190S), RhoB (residues 1–190, C190S), and
RhoC (residues 1–191, C191S) were expressed in E. coli and purified essentially as previously
described (15,36,37). Size-exclusion chromatography was used for all recombinant protein
preparations to ensure samples eluted as monodispersed species of correct molecular weight.
All recombinant protein concentrations were determined using the A280 method with extinction
coefficients calculated using the ProtParam tool (ExPASy Molecular Biology Server (38)),
analyzed by SDS-PAGE to confirm concentration and ensure purity, and subsequently stored
at −80 °C.
Guanine Nucleotide Exchange Assays
The guanine nucleotide exchange activity of purified RhoGEFs was determined using a kinetic,
fluorescence-based assay with Rho GTPases (RhoA, RhoB, RhoC, Rac1, Cdc42) that were
preloaded with BODIPY FL-conjugated GDP (BODIPY-GDP, Molecular Probes) essentially
as previously described (39). All exchange assays were performed using an LS-55 fluorescence
spectrometer (PerkinElmer) with wavelengths set at λex = 500 nm (slits = 5 nm),λem = 511 nm
(slits = 5 nm), and quartz cuvettes thermostatted at 20 °C while constantly stirred. Reactions
were carried out in exchange buffer consisting of 20 mM Tris, pH 7.5, 200mM NaCl, 10mM
MgCl2, 5% (v/v) glycerol, and 10µM GDP. For each exchange assay, BODIPY-GDP-preloaded
Rho GTPases (200 nM) were allowed to equilibrate in exchange buffer. Then 30µM AlF4
(30µM AlCl3+10mM NaF) and/or heterotrimeric G proteins at the indicated concentrations were
added. The presence of AlF4 had no impact on the spontaneous exchange rate of Rho GTPases
and was used to selectively activate heterotrimeric G proteins. Finally, the guanine nucleotide
exchange reaction was initiated by the manual addition of the RhoGEF at the indicated
concentrations and the exchange reaction was monitored in real time until completion. The
observed exchange rates (kobs) were then calculated for each condition by fitting the change
in relative fluorescence intensity over time for a given condition to a single-phase exponential
decay using Prizm data analysis software (GraphPad). Exchange data depicted in bar graphs
are the mean ± S.D. for each condition, conducted in triplicate. Representative real time kinetic
exchange data depicted in curves are normalized as follows: relative fluorescence units prior
to addition of RhoGEF (100% BODIPY-GDP bound) and relative fluorescence units at reaction
completion (0% BODIPY-GDP bound).
Surface Plasmon Resonance Binding Studies
All surface plasmon resonance (SPR) studies were performed using a Biacore 3000 instrument
(GE Healthcare). An anti-GST antibody was covalently coupled to a CM5 Biacore chip per
the manufacturer’s protocol. Binding studies were performed in SPR buffer consisting of 20
mM HEPES, pH 7.5, 150 mM NaCl, 10 mM MgCl2, 0.05% (v/v) Nonidet P-40, 100 µM GDP, and
30 µM AlF4 (30 µM AlCl3 + 10 mM NaF). GST fusion binding surfaces were subsequently
generated for individual flow cells by the application of GST only, or the GST-tagged
p63RhoGEF constructs GST-DHExt and GST-DH-PH. To generate SPR-based binding
isotherms, an analyte consisting of 10 µM Gαq in AlF4-containing SPR buffer was flowed over
each surface; background binding to the GST only surface was subsequently subtracted from
each condition and the corresponding relative units were plotted.
Fluorescence Polarization Binding Studies
Apeptide spanning the conserved PH domain extension of p63RhoGEF was synthesized and
high pressure liquid chromatography purified by the Tufts University peptide core facility.
This peptide consisted of an N-terminal fluorescein moiety followed by a β-alanine linker and
residues 467–493 of human p63RhoGEF followed by a C-terminal amide group. Gαq or Gαi
were added at varying concentrations to a 96-well plate containing 5 nM peptide in buffer
consisting of 20 mM Tris, pH 7.5, 200 mM NaCl, 20 mM MgCl2, 0.05% (v/v) Nonidet P-40, 30
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µM GDP, and 30 µM AlF4 (30 AlCl3+10mM NaF) with a total volume of 200µl. Each condition
was allowed to equilibrate at 25 °C for ~15 min before polarization was determined using a
PHERAstar fluorescence microplate reader (BMG Labtech) using the polarization mode. The
excitation laser (λex = 485 nm) was vertically polarized and the subsequent fluorescence
emission intensity (λem= 520 nm) was observed through a polarizer orientated parallel or
perpendicular to the excitation vector. Polarization (P) was then calculated using the formula:
p=(I‖−I⊥)/(I‖+I⊥), where I‖is the intensity of the parallel component and I⊥ is the intensity of
the perpendicular component of the emitted light (40). Peptide in the absence of heterotrimeric
G protein was used to adjust the gain prior to data collection.
RESULTS
Sequence Analysis Reveals a Highly Conserved Extension of the DH-associated PH Domain
of p63RhoGEF
Unlike the majority of the 69 human Dbl-family GEFs, p63RhoGEF lacks any additional
signaling domains outside of the canonical DH-PH cassette that defines this family. To identify
conserved regions that may impart signaling properties or suggest modes of regulation for
p63RhoGEF, we generated a multiple sequence alignment using Clustal-X (41) for eight
representative p63RhoGEF orthologs and projected the sequence conservation for each residue
onto the predicted domain architecture (Fig. 1A). The three-dimensional structure of PH
domains is well characterized and takes on a β-sandwich fold capped on one side by a C-
terminal α-helix, termed αC (17). Interestingly, the predicted αC helix of p63RhoGEF has a
highly conserved extension, which is predicted to be unstructured and is not considered an
integral part of the PH domain based on sequence analysis (Fig. 1A). The strict conservation
of this region and its proximity to the PH domain led us to hypothesize that this unique extension
may be essential for regulating the exchange activity of p63RhoGEF. Based on these sequence
analysis studies, we generated several p63RhoGEF truncation mutant constructs (Fig. 1A) and
purified recombinant protein components to near homogeneity for use in our subsequent
biochemical/biophysical analyses (Fig. 1B).
The Guanine Nucleotide Exchange Activity of p63RhoGEF Is Autoinhibited by the DH-
associated PH Domain
We tested p63RhoGEF truncation mutants for their ability to promote guanine nucleotide
exchange using RhoA as a substrate GTPase to investigate the mechanism of autoregulation.
The exchange activities of p63RhoGEF constructs encompassing the DH-Ct, DH-Ext, and DH-
PH were similarly activating toward RhoA, yielding an ~2–3-fold increase in the exchange
rate over the spontaneous exchange rate of RhoA alone (Fig. 2). Full-length p63RhoGEF was
similar in its activation of RhoA (data not shown). These results rule out possible regulation
by inhibitory sequences, which have been well characterized for Vav and more recently, Tim-
family RhoGEFs (42). However, under identical conditions, the DH construct was ~22-fold
more active than the spontaneous exchange rate of RhoA alone (Fig. 2), implicating the PH
domain as a negative regulator of p63RhoGEF exchange activity. To generate a soluble
p63RhoGEFDHfragment, we used a TEV-cleavable MBP fusion at the N terminus; both MBP
fusion and TEV-treated DH constructs retained similar activity toward RhoA. Whereas there
is conflicting literature regarding the regulatory role of the PH domain of p63RhoGEF, our
results are in accordance with previous studies that suggest an autoinhibitory role (43,44).
Activated Gαq Directly Stimulates the Guanine Nucleotide Exchange Activity of p63RhoGEF
Whereas Lutz and colleagues (30) elegantly demonstrated that Gαq/11 synergizes with
p63RhoGEF to activate RhoA signaling pathways in cells, the authors did not explore the
underlying mechanism. Therefore, we used previously published methods (33) to generate
soluble recombinant Gαq protein to test the hypothesis that Gαq directly stimulates p63RhoGEF
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activity. The new Gαi/q chimera contains the N-terminal α-helix of Gαi1 followed by a TEV
cleavage site fused to the N terminus of Gαq-(8–359); treatment with TEV-generated
recombinant soluble Gαq protein with amino acid sequence from Ala8 to the end and was
purified with high purity (Fig. 1B). In contrast to the previous Gαq chimera (33), this new
chimera demonstrated phospholipase C-β stimulating activity in vitro.5 Subsequently, we
established that purified Gαq directly stimulates the exchange activity of autoinhibited
p63RhoGEF (Fig. 3, A and B). The exchange activity of each p63RhoGEF truncation mutant
construct in the presence of inactive GDP-bound Gαq or AlF4 alone was comparable with the
control exchange rate, comprising a 2–3-fold activation over the spontaneous exchange rate of
RhoA alone. However, the DH-Ct and DH-Ext constructs of p63RhoGEF were robustly
stimulated by AlF4-activated Gαq by~26-fold over the spontaneous exchange rate of RhoA
alone. Additionally, full-length p63RhoGEF was similarly activated by AlF4-activated Gαq;
however, the purity of the full-length construct was diminished due to N-terminal degradation
(data not shown). Interestingly, the DH-PH construct lacking the conserved extension of the
PH domain was not stimulated by AlF4-activated Gαq. This lack of Gαq-mediated stimulation
of the DH-PH fragment was not simply due to misfolding as the basal activity closely resembled
that of the DH-Ct and DH-Ext constructs. Additionally, the DH construct lacking the
autoinhibitory PH domain was not further stimulated by addition of AlF4-activated Gαq (Fig.
3C). Most likely, the DH construct represents constitutively active p63RhoGEF. The exchange
rates catalyzed by p63RhoGEF (DH-Ext) in the presence of increasing amount of AlF4-
activated Gαq (Fig. 4A), were used to generate a dose-response curve that yielded an EC50 of
~951 nM for the activation of p63RhoGEF by AlF4-activated Gαq (Fig. 4B). Based on these
results, the DH-Ext construct comprises the minimal region of p63RhoGEF that is both basally
autoinhibited and activated by AlF4-activated Gαq; subsequent experiments utilized this DH-
Ext construct.
Next, we identified key residues within p63RhoGEF essential for Gαq-mediated activation
using site-directed mutagenesis of the conserved PH domain extension (residues 466–483,
alanine 474 was not mutated). In particular, alanine substitutions in the context of DH-Ext at
Phe471, Leu472, Leu475, Pro478, and Ile479 substantially diminished the capacity for AlF4-
activated Gαq to stimulate the exchange activity of p63RhoGEF compared with wild-type (Fig.
5A). The basal exchange activity of these point mutants (i.e. in the absence of activated Gαq)
was comparable with the basal exchange activity of wild-type p63RhoGEF and proteins eluted
as mono-dispersed species of correct molecular weight when analyzed by size-exclusion
chromatography and SDS-PAGE (Fig. 5C), indicating proper folding and protein integrity.
Interestingly, mutations most deleterious to Gαq-mediated stimulation of p63RhoGEF display
helical periodicity and appear to encompass the single face of an α-helix when analyzed using
bioinformatics-based methods (ExPASy Molecular Biology Server (38)) (Fig. 5B). This was
an unexpected finding as this region is predicted to be unstructured based on secondary
structure prediction methods. We hypothesize that this normally disordered extension
undergoes a conformational change to an α-helix upon binding Gαq.
We then performed binding assays to determine whether this conserved extension was
important for directly engaging activated Gαq or merely contributed to allosteric activation of
the DH domain. We used both analytical size-exclusion chromatography (Fig. 6A) as well as
SPR analysis (Fig. 6B) to show that the p63RhoGEF DH-Ext binds AlF4-activated Gαq with
a high affinity, whereas the DH-PH construct lacking the extension motif does not interact with
activated Gαq. Further analysis of the SPR-generated binding isotherms indicate that the DH-
Ext construct bound activated Gαq with an association rate constant of 0.12 and a dissociation
rate constant of 0.039. Whereas these results indicate that the C-terminal extension was
5T. Kawano and T. Kozasa, unpublished results.
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necessary for binding activated Gαq, they do not address whether it was sufficient for binding.
Therefore we generated a peptide corresponding to the C-terminal extension of p63RhoGEF
(residues 467– 493) and showed that this peptide was sufficient to bind AlF4-activated Gαq
using a polarization/anisotropy-based binding assay, whereas AlF4-activated Gαi did not bind
this peptide (Fig. 6C). However, the relatively low affinity for this interaction suggests to us
that additional regions outside of this minimal peptide are required for full engagement of
activated Gαq by p63RhoGEF.
G Protein Specificity Determinants for p63RhoGEF
To determine the full spectrum of heterotrimeric G proteins specific for p63RhoGEF, we tested
a panel of highly purified recombinant Gα-subunits for their ability to directly stimulate the
exchange activity of p63RhoGEF. As expected, the exchange activity of p63RhoGEF (DH-
Ext) was not affected by the addition of high concentrations of AlF4-activated Gαi, Gαo,
Gαs, Gαt, and Gα13 (Fig. 7A). The resulting exchange rates were comparable with that of the
control exchange rate in the absence of heterotrimeric G proteins, comprising a 2–3-fold
activation over the spontaneous exchange rate of RhoA alone. Only Gαq robustly stimulated
the guanine nucleotide exchange activity in an AlF4-dependent manner. Secondary studies,
including AlF4-dependent binding of effector proteins, were used to confirm the activity of
each heterotrimeric G protein used (34,35); the purity and concentration of each heterotrimeric
G protein used was additionally confirmed using SDS-PAGE analysis (Fig. 7B). Currently, we
are developing baculoviral expression constructs to probe additional Gαq family members
(e.g. Gα11 and Gα14) for activation of p63RhoGEF.
The substrate Rho GTPase specificity for p63RhoGEF has not been well characterized.
Therefore, we investigated the substrate Rho GTPase specificities for Gαq-activated
p63RhoGEF. High concentrations of AlF4-activated Gαq in combination with p63RhoGEF
(DH-Ext) did not promote guanine nucleotide exchange on BODIPY-GDP-preloaded Rac1
(Fig. 7C) or Cdc42 (Fig. 7D). The activity of both Rac1 and Cdc42 were confirmed using the
RhoGEFs Tiam1 and Dbs, respectively (Fig. 7, C and D). Additionally, we demonstrated that
Gαq-activated p63RhoGEF catalyzes guanine nucleotide exchange on Rho isozymes RhoB
and RhoC (Fig. 7E). This activation of RhoB and RhoC by p63RhoGEF was comparable with
that observed with RhoA, implicating p63RhoGEF as a Rho isoform-specific exchange factor.
The Rho-specific Exchange Activity of the C-terminal DH-PH Cassette of Trio Is Similarly
Stimulated by Activated Gαq
Because there is a large precedent for RhoA signaling downstream of Gαq we hypothesized
additional Dbl-family members related to p63RhoGEF may also be directly by activated
Gαq. Therefore, we used the basic local alignment search tool (45) to identify additional
proteins homologous to p63RhoGEF that may also interact directly with activated Gαq. We
identified the Dbl-family proteins Trio and Kalirin as the closest paralogs to p63RhoGEF. More
importantly, Trio and Kalirin were the only other proteins that contain the highly conserved
C-terminal extension of the PH domain (residues 471– 483), which is required for direct
engagement of activated Gαq by p63RhoGEF. Trio and Kalirin are unique in that they are the
only Dbl-family members that contain two independent DH-PH cassettes (14). The N-terminal
DH-PH cassette is Rac1/RhoG-specific, whereas the C-terminal DH-PH cassette is RhoA-
specific (46,47). Only the C-terminal RhoA-specific and not the N-terminal Rac1/RhoG-
specific DH-PH cassette of Trio and Kalirin bear significant homology to p63RhoGEF (Fig.
8A). Interestingly, residues within the PH domain extension that were essential for p63RhoGEF
activation by Gαq (Phe471, Leu472, Leu475, Pro478, and Ile479) are 100% conserved in Trio and
Kalirin. We subsequently determined that AlF4-activated Gαq can directly stimulate the RhoA-
specific guanine nucleotide exchange activity of the C-terminal DH-PH cassette of Trio (Trio-
C DH-Ext) by ~2-fold over inactive GDP-bound Gαq or AlF4 alone (Fig. 8, B and C). This
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stimulation by Gαq was not nearly as robust as that seen for p63RhoGEF, suggesting that other
mechanisms may facilitate the interaction of activated Gαq with Trio. Alternatively, Trio-C
DH-Ext possesses a higher capacity to catalyze guanine nucleotide exchange upon RhoA
relative to the equivalent fragment of p63RhoGEF. Therefore, AlF4-activated Gαq is
stimulating a form of Trio that is already highly exchange-competent such that the measured
enhancement by Gαq belies the full potential of Gαq to activate full-length and, presumably,
fully autoinhibited Trio.
DISCUSSION
There is considerable evidence suggesting that Gα12/13 and Gαq/11 family members
independently activate RhoA signaling in response to extracellular stimuli (18,19,21,26–29).
Whereas the Gαq/11-specific pathway has remained poorly understood, numerous studies
indicate that Gα12/13 engage the RGS domain of the p115 family members and directly
stimulate their RhoA-specific exchange activity (23). The p115 family RhoGEFs are the only
Dbl-family members that contain an RGS domain; however, previous efforts to implicate p115
family members as Gαq/11-responsive RhoGEFs have been largely unsuccessful. 6 The recent
finding that Gαq/11 synergizes with p63RhoGEF to promote Rho signaling in cells was
significant given that Gαq-responsive RhoGEFs have remained elusive. However, given that
p63RhoGEF lacks any semblance of an effector-binding site for activated heterotrimeric G
proteins, such as an RGS domain, there was no precedent for a direct mode of regulation. Here
we provide evidence that Gαq directly engages and stimulates the Dbl-family member
p63RhoGEF via novel mechanisms distinct from that previously described for the RGS
containing RhoGEFs of the p115 family.
Like numerous Dbl-family members before it, p63RhoGEF was first identified during an
oncogenic screen based on its ability to robustly transform NIH3T3 cells (48). An N-terminal
truncation of p63RhoGEF that most likely arises by alternative splicing has been previously
described in the literature as GEFT. GEFT lacks the first 106 amino acids, but is nevertheless,
considered functionally redundant with the full-length protein, p63RhoGEF. Previous studies
have implicated p63RhoGEF/GEFT in muscle regeneration and myogenesis (43), regulation
of cardiac sarcomeric actin (49), cell proliferation and migration (50), dendritic spine formation
(51), and neurite outgrowth (52). Collectively, these suggest p63RhoGEF is an important
regulator of actin in excitatory tissues such as muscle and neurons. Interestingly, Gαq-mediated
activation of RhoA is also implicated in the pathophysiology of myocardial hypertrophy (6–
8). Additional studies are needed to explore the contribution of p63RhoGEF to these and other
physiological responses.
Our results support previous reports suggesting an autoinhibitory role for the PH domain of
p63RhoGEF. Previous studies have demonstrated that the DH domain of p63RhoGEF activated
serum response factor-dependent gene transcription more robustly than full-length protein
(44). Previous work has also shown that the PH domain functioned in trans as a dominant-
negative by reducing serum response factor-dependent gene transcription mediated by full-
length (43) or isolated DH domains (44). However, conflicting reports also suggest the PH
domain is essential for induction of stress fibers (49); additional studies may be needed to
explore the membrane-targeting capacity of the PH domain and other associated in vivo roles.
We hypothesize that p63RhoGEF is autoinhibited in a manner analogous to that described for
Sos1. The x-ray crystal structure of the Sos1 DH-PH cassette indicates that the PH domain
folds back onto the DH domain, thereby occluding access to the Rho GTPase binding site and
inhibiting activity (53). An extended linker region that joins the adjacent DH and PH domains
6R. J. Rojas and J. Sondek, unpublished results.
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facilitates this intramolecular interaction within Sos1. However, p63RhoGEF bears no
significant homology to the regions of Sos1 responsible for intramolecular binding.
Our results clarify conflicting literature regarding the Rho GTPase substrate specificity of
p63RhoGEF. Previous reports suggest that p63RhoGEF is specific for RhoA in REF52
fibroblasts (49), H9C2 cardiomyocytes (49), J82 epithelial cells (44), and HEK-293 cells
(30,44). Yet, other studies also characterized p63RhoGEF as specific for Rac1/Cdc42 in COS-7
and HeLa cells (50) or promiscuous for RhoA/Rac1/Cdc42 in C2C12 muscle cells (43) and
N2A neuroblastoma cells (51,52). A high degree of cross-talk within the Rho subfamily
typically complicates the interpretation of these cell-based specificity studies. Furthermore,
previous in vitro analysis of p63RhoGEF specificity have relied on suboptimal methodology
and have produced results suggesting either RhoA (44,49) or Rac1/Cdc42 specificity (50).
Therefore, we performed in vitro characterization of substrate Rho GTPases using highly
purified components with a robust real-time assay (39) to demonstrate that p63RhoGEF
specifically activates the Rho isozymes RhoA, RhoB, and RhoC with similar potency. This
result is in accordance with studies demonstrating the specific activation of RhoA, and not
Rac1 or Cdc42, downstream of Gαq/11 (18,19,21,26–29). Whereas the three Rho isozymes are
highly homologous, recent evidence suggests they are not functionally redundant (54);
additional studies are required to determine the functional relevance of RhoB/RhoC activation
downstream of Gαq/11 and p63RhoGEF. Interestingly, the p63RhoGEF gene, GEFT, bears the
official moniker RAC/CDC42 exchange factor; our studies indicate this is a misnomer.
Based on sequence similarity, strict conservation of the PH domain extension, and evidence
that Trio-C is directly stimulated by activated Gαq we hypothesize that p63RhoGEF, Trio, and
Kalirin represent a novel subset of Dbl-family Rho-GEFs regulated by Gαq/11. Trio and Kalirin
share remarkable similarity with each other in their domain architecture and are both essential
regulators of axon guidance and neuronal cell migration during neuronal development. A
majority of studies on Trio and Kalirin have focused on the N-terminal Rac1/RhoG-specific
DH-PH cassette; little is known about the C-terminal RhoA-specific DH-PH cassette.
Interestingly, Trio-like proteins have been highly conserved throughout evolution. For
example, the Trio orthologs in Caenorhabditis elegans, UNC-73, and Drosophila, d Trio, are
essential for proper neuronal/axonal development (55,56). Whereas no current evidence
directly implicates Trio and Kalirin in Gαq/11-mediated signaling pathways, future studies in
model organisms such as Drosophila and C. elegans may lend credence to this intriguing
notion.
In summary, the studies presented here uncover a novel mode of regulation for Dbl-family
GEFs by heterotrimeric G proteins and suggests that, in addition to p63RhoGEF, Kalirin and
Trio may also signal downstream of Gαq/11. Now, p63RhoGEF joins a small group of Dbl-
family members that have been shown to be directly activated by heterotrimeric signaling
components. Ongoing crystallographic studies within our group should soon uncover the
molecular details underlying p63RhoGEF activation by Gαq at atomic resolution.
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FIGURE 1. Sequence analysis of p63RhoGEF
A, a multiple sequence alignment for p63RhoGEF was generated from eight different species
and used to calculate the percent identity for each residue using Clustal-X (41); these values
are depicted as a bar graph projected onto the domain architecture of p63RhoGEF. The detailed
portion of the multiple sequence alignment (spanning residues 443–499 of human
p63RhoGEF) highlights a conserved extension to the C-terminal αC helix of the PH domain.
Also shown is the predicted secondary structure for this region comprising the β7 β-sheet, αC
α-helix, and unstructured regions depicted as a black line; truncation mutants generated for
this study are also shown at the top with construct borders in parentheses. B, equal amounts
(~5 µg) of purified protein components were analyzed by SDS-PAGE and stained with
Coomassie Blue to confirm purity and concentration; molecular weight standards are also
shown.
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FIGURE 2. The PH domain negatively regulates the exchange activity of p63RhoGEF
RhoA alone, spontaneous nucleotide exchange of 200 nM BODIPY-GDP-preloadedRhoAin the
absence of p63RhoGEF; all others, 200 nM of the indicated p63RhoGEF truncation mutant was
added to 200 nM BODIPYGDP- preloaded RhoA to initiate guanine nucleotide exchange. Also
shown is the calculated fold-activation over RhoA alone for each construct. All curves are
representative of experiments performed in triplicate. Bod, BODIPY.
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FIGURE 3. Gαq directly stimulates the exchange potential of p63RhoGEF
A, RhoA alone, spontaneous nucleotide exchange of RhoA in the absence of p63RhoGEF; all
others, 200 nM of the indicated p63RhoGEF truncation mutant was added to 200 nM BODIPY-
GDP-preloaded RhoA in the presence or absence of 30µM AlF4 and 200 nM Gαq. Bar graphs
depict the mean±S.D. for each condition conducted in triplicate. B, representative real-time
kinetic data for the DH-Ext construct used to calculate exchange rates. C, the exchange activity
of 200 nM p63RhoGEF DH upon 200 nM BODIPY-GDP-preloaded RhoA in the presence and
absence of 200 nM AlF4-actived Gαq; shown is the mean ± S.D., n.s., not significant by pairwise
t test. Bod, BODIPY.
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FIGURE 4. Dose-response curve for Gαq-mediated stimulation of p63RhoGEF
A, the guanine nucleotide exchange activity of 200 nM p63RhoGEF (DH-Ext) upon 200 nM
BODIPY-GDP-preloaded RhoA was determined in the presence of increasing amounts of
AlF4-activated Gαq (6.25 nM to 5 µM); shown are representative traces for each concentration
used. B, the calculated exchange rates (kobs) were plotted against Gαq concentration and fit to
a one-site binding curve; data are the mean ± S.D. of two independent experiments. Bod,
BODIPY.
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FIGURE 5. Mutational analysis of the conserved PH domain extension within p63RhoGEF
A, alanine substitutions were made within the conserved PH domain extension of p63RhoGEF
in the context of DH-Ext. 200 nM of each point mutant was added to 200 nM BODIPY-GDP-
preloaded RhoA in the presence of 300 nM Gαq and 30 µM AlF4 prior to measuring exchange
rates; the exchange activity of 200 nM wild-type (wt) p63RhoGEF (DH-Ext) in the presence
and absence of 300 nM Gαq and 30 µM AlF4 is also shown. Bar graphs depict the mean ± S.D.
for the calculated exchange rate of each condition, conducted in triplicate; the most deleterious
point mutants are highlighted. B, sequence containing the conserved PH domain extension
(residues 466– 483, ESQRDFLNALQSPIEYQR) was modeled as an α-helix and displayed as
a helical wheel (ExPASy Molecular Biology Server (38)) with the corresponding residue
numbers, highlighted is the region predicted to bind Gαq. C, equal amounts (~10 µg) of purified
p63RhoGEF point mutants used in A were analyzed by SDS-PAGE and stained with Coomassie
Blue to confirm purity and concentration; molecular weight standards are also shown (note
that alanine 474 was not mutated).
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FIGURE 6. The conserved PH domain extension of p63RhoGEF is essential for direct binding of
activated Gαq
A, analytical gel-exclusion chromatography was used to isolate a heterodimeric complex of
AlF4-activated Gαq with GST-tagged p63RhoGEF (GST-DH-Ext); under identical conditions
the GST-DH-PH construct did not complex with AlF4-activated Gαq (lower panel). B, GST-
tagged p63RhoGEF truncation constructs (GSTDH- Ext and GST-DH-PH) were immobilized
onto the surface of the Biacore chip; analyte consisting of 10 µM AlF4-activated Gαq was then
flowed over each surface while measuring surface plasmon resonance. C, a fluorophore-
conjugated peptide corresponding to the conserved PH domain extension of human
p63RhoGEF (residues 467– 493) was used in a polarization/anisotropy-based assay to show
direct dose-dependent binding to AlF4-activated Gαq.
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FIGURE 7. Specificity of p63RhoGEF for heterotrimeric Gα-subunits and substrate Rho GTPases
A, 200 nM p63RhoGEF (DH-Ext) was added to mixtures containing 200 nM BODIPY-GDP-
preloaded RhoA in the presence or absence of 30 µM AlF4 and 500 nM of the indicated Gα-
subunit (Gαq, Gαi, Gαo, Gαs, Gαt, and Gα13). B, equal amounts (~5µg) of purified
heterotrimeric G protein components used in A were analyzed by SDS-PAGE and stained with
Coomassie Blue to confirm purity and concentration; molecular weight standards are also
shown. C and D, 500 nM p63RhoGEF (DH-Ext), 500 nM Gαq, and 30αM AlF4 were added to
reaction mixtures containing 200 nM BODIPY-GDP-preloaded Rac1 (C) and Cdc42 (D). 500
nM Tiam1 (DH-PH) was added to Cand 50 nM Dbs (DH-PH) was added to Dto confirm Rac1 and
Cdc42 activity, respectively. E, RhoB alone, RhoC alone, spontaneous nucleotide exchange in
the absence of p63RhoGEF; all others, 200 nM p63RhoGEF (DH-Ext) was added to reaction
mixtures containing 200 nM BODIPY-GDP-preloaded RhoB or RhoC in the presence or
absence of 30 µM AlF4 and 200 nM Gαq. Bar graphs depict the mean ± S.D. for the calculated
exchange rate (kobs) of each condition, conducted in triplicate. Bod, BODIPY.
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FIGURE 8. Gαq directly stimulates the guanine nucleotide exchange activity of Trio-C
A, domain architecture of p63RhoGEF and its closest paralogs, Trio and Kalirin and multiple
sequence alignment of the highly conserved C-terminal extension of the PH domain; also
shown is the predicted secondary structure for the region of the PH domain proximal to the
extension motif (β7,β-sheet;αC, C-terminalα-helix; black line, unstructured). B, the guanine
nucleotide exchange assay was used to determine the exchange potential (kobs) of Trio in
response to AlF4-activated Gαq. RhoA alone, spontaneous nucleotide exchange for 200 nM
BODIPY-GDP-loaded RhoA in the absence of Trio; all others, 200 nM Trio (DH-Ext) was
added to 200 nM BODIPY-GDP-loaded RhoA in the presence or absence of 30 µM AlF4 and 2
µM Gαq as indicated. Bar graphs depict the mean ± S.D. for the calculated exchange rate
(kobs) of each condition, conducted in triplicate; asterisk (*) denotes p < 0.02 compared with
noGαq/AlF4 present by pairwise t test. C, representative real-time kinetic data used to calculate
exchange rates in B. Bod, BODIPY.
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